Lewy Body Dementia
Zonisamide as an adjunct to levodopa therapy improves parkinsonism in patients with dementia with Lewy bodies.
While parkinsonian disorders share a common mechanism of protein aggregation, manifestations are quite varied.
Patients with multiple system atrophy with parkinsonism face the greatest risk for death among synucleinopathies.
Increasing severity of AD pathology inversely correlated to decreases in time from motor symptoms to dementia onset and death.
Patients with mild cognitive impairment with preserved hippocampal volume are at increased risk for dementia with Lewy bodies vs Alzheimer disease.
According to a 2010 report based on a survey of caregivers of people with DLB, 78% of cases were initially misdiagnosed.
OCT can precisely measure changes to the retinal structure.
Over 60% of people with Parkinson's disease will have REM sleep behavior disorder, endangering them and their partners during the night.
Monoclonal antibodies targeting tau and beta amyloid in Alzheimer's disease may also benefit other neurodegenerative diseases.
The results suggest that specific Alzheimer's therapies may need to be developed to address differences in pathology.
Williams' suicide emphasizes the importance of support for patients with Lewy Body Dementia and their families.
A coroner's report documenting the death of actor Robin Williams revealed that he had Lewy body dementia.
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies